Dr Qianxin Wu
Staff Scientist
Qianxin joined Sanger Human Genome Editing R&D team since 2017. She became a joint member between Human Genome Editing R&D team and Cellular Genetics in 2022. Currently, she is leading two projects on the following two areas:
- Create a novel biotechnology for personalised CRISPR screens. (Sanger translational grant)
- Develop sequencing method directly linking genotype to phenotype at single cell level using microfluidic platform. (Industry grant with ACXEL)
At Sanger, Qianxin developed dead Cas9-based epigenetic modification systems (dCas9-EM) and used of thousands of uniquely inserted DNA barcodes to unbiasedly analyse context dependent dCas9-EM effects in human iPSCs and iNeurons. Her research deciphered the rules underling CRISPR activation.
During COVID-19 pandemic, she developed INSIGHT technology in order to provide a combined point-of-care and centralised sequencing based testing solution.
Prior to Sanger, Qianxin was a postdoc in Professor Tudor Fulga’s lab, Weatherall Institute, Oxford University. During her postdoc work, she has developed a genome engineering discovery platform, namely GenERA, enabling a systems-level functional characterisation of primary RNA regulatory networks.
Qianxin completed her Phd under supervision of Professor Nigel Gooderham at Imperial College London. During her PhD, she studied how a strong metabolic perturbation could change the entire metabolic network in a mouse model and whether gene expression controlled by microRNAs could explain these changes.
My timeline
Joint member between Human Genome Editing R&D and Cellular Genetics
Joined Sanger Institute, Human Genome Editing R&D team.
Started Postdoc, Weatherall Institute of Molecular Medicine, Oxford University
Started PhD, Biomolecular Medicine, Center for Computational and Systems Medicine, Imperial College London